- Home
- TNYA vs IPHA Comparison
TNYA vs IPHA Comparison
Compare TNYA & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNYA | IPHA |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9M | 169.6M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | TNYA | IPHA |
|---|---|---|
| Price | $0.80 | $1.71 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 3 |
| Target Price | ★ $5.25 | $5.00 |
| AVG Volume (30 Days) | ★ 3.9M | 18.3K |
| Earning Date | 03-09-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | N/A | $43.90 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.36 | $1.63 |
| 52 Week High | $2.35 | $2.63 |
Technical Indicators
Market Signals| Indicator | TNYA | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.77 | N/A |
| Support Level | $0.75 | N/A |
| Resistance Level | $0.94 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 39.60 | 0.00 |
Price Performance
Historical ComparisonAbout TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.